These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38102912)
1. Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience. Halacoglu A; Serefhanoglu S J Cancer Res Ther; 2024 Apr; 20(3):904-908. PubMed ID: 38102912 [TBL] [Abstract][Full Text] [Related]
2. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609 [TBL] [Abstract][Full Text] [Related]
4. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach. Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience. Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994 [TBL] [Abstract][Full Text] [Related]
7. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [TBL] [Abstract][Full Text] [Related]
8. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Smardova L; Engert A; Haverkamp H; Raemakers J; Baars J; Pfistner B; Diehl V; Josting A Leuk Lymphoma; 2005 Jul; 46(7):1017-22. PubMed ID: 16019552 [TBL] [Abstract][Full Text] [Related]
9. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Harris RE; Termuhlen AM; Smith LM; Lynch J; Henry MM; Perkins SL; Gross TG; Warkentin P; Vlachos A; Harrison L; Cairo MS Biol Blood Marrow Transplant; 2011 Feb; 17(2):249-58. PubMed ID: 20637881 [TBL] [Abstract][Full Text] [Related]
10. Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study. Sarici A; Erkurt MA; Kuku I; Gok S; Bahcecioglu OF; Bicim S; Berber I; Kaya E; Ozgul M Transfus Apher Sci; 2021 Oct; 60(5):103251. PubMed ID: 34419358 [TBL] [Abstract][Full Text] [Related]
11. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation. Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612 [TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778 [TBL] [Abstract][Full Text] [Related]
13. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. Benboubker L; Cartron G; Roingeard F; Delain M; Degenne M; Linassier C; Hérault O; Truglio D; Bout M; Petit A; Brémond JL; Desbois I; Colombat P; Binet C; Domenech J Exp Hematol; 2003 Jan; 31(1):89-97. PubMed ID: 12543111 [TBL] [Abstract][Full Text] [Related]
14. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts. Holmberg LA; Linenberger M; Connelly-Smith L Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104 [TBL] [Abstract][Full Text] [Related]
15. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691 [TBL] [Abstract][Full Text] [Related]
16. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854 [TBL] [Abstract][Full Text] [Related]
18. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
19. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684 [TBL] [Abstract][Full Text] [Related]
20. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. Han X; Ma L; Zhao L; He X; Liu P; Zhou S; Yang J; Qin Y; Yang S; Yao J; Shi Y J Clin Apher; 2012; 27(2):64-74. PubMed ID: 22298390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]